Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
35.09
-0.16 (-0.45%)
Apr 10, 2026, 1:23 PM EDT - Market open
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
The 5 analysts that cover Collegium Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $51.4, which forecasts a 46.48% increase in the stock price over the next year. The lowest target is $37 and the highest is $60.
Price Target: $51.4 (+46.48%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Collegium Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +70.99% | Mar 20, 2026 |
| Needham | Needham | Strong Buy Reiterates $54 → $56 | Strong Buy | Reiterates | $54 → $56 | +59.59% | Mar 19, 2026 |
| Needham | Needham | Strong Buy Maintains $56 → $54 | Strong Buy | Maintains | $56 → $54 | +53.89% | Feb 26, 2026 |
| Barclays | Barclays | Buy Maintains $58 → $56 | Buy | Maintains | $58 → $56 | +59.59% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $46 → $60 | Strong Buy | Reiterates | $46 → $60 | +70.99% | Jan 9, 2026 |
Financial Forecast
Revenue This Year
843.09M
from 780.57M
Increased by 8.01%
Revenue Next Year
802.28M
from 843.09M
Decreased by -4.84%
EPS This Year
7.44
from 1.73
Increased by 328.80%
EPS Next Year
6.52
from 7.44
Decreased by -12.41%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 907.4M | 998.6M | |||
| Avg | 843.1M | 802.3M | |||
| Low | 789.7M | 611.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 16.3% | 18.4% | |||
| Avg | 8.0% | -4.8% | |||
| Low | 1.2% | -27.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 7.93 | 8.19 | |||
| Avg | 7.44 | 6.52 | |||
| Low | 6.80 | 4.32 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 357.3% | 10.1% | |||
| Avg | 328.8% | -12.4% | |||
| Low | 292.0% | -41.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.